Novel molecules for efficient photodynamic therapy
We are developing a new generation of photosensitizers to be used in photodynamic therapy (PDT) to treat more cancer types with minimum side-effects.
Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer
Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
G4 Cancer Cure Project – Increased patient survival in breast cancer
Triple-negative breast cancer, a hard-to-treat cancer subtype more common in young women, needs improved drugs to increase patient survival. Our innovation, a small molecule that targets G-quadruplex DNA structures, will selectively eradicate triple-negative breast cancer cells, and thereby improve treatment.
Metacurum Biotech AB – Novel antibody treatment for metastatic cancers
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Medsens AB – exact real time prostate cancer diagnosis
By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.
Betulaceae Pharmaceuticals – improved quality of life during cancer
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
Hiloprobe AB – improved colorectal cancer diagnostics
Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.